While our in vivo studies were of preventive nature currently ongoing experiments addressing the question if pep−MHC-Ig dimer immunization induced T cell responses demonstrate the same efficiency on already established tumours and if anti-CD40 mAb can be efficiently substituted to avoid potential generation of auto-reactive T cell responses. The gene discussed is CD40; the disease is neoplasm.